The Myopia drugs in development market research report provides comprehensive information on the therapeutics under development for Myopia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Myopia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Myopia and features dormant and discontinued products.
GlobalData tracks 31 drugs in development for Myopia by 31 companies/universities/institutes. The top development phase for Myopia is phase iii with ten drugs in that stage. The Myopia pipeline has 30 drugs in development by companies and one by universities/ institutes. Some of the companies in the Myopia pipeline products market are: Cellix Bio, Tsubota Laboratory and Santen Pharmaceutical.
The key targets in the Myopia pipeline products market include Cholinergic Receptor Muscarinic, Adenosine Receptor, and Retinal Dehydrogenase 2.
The key mechanisms of action in the Myopia pipeline product include Cholinergic Receptor Muscarinic Antagonist with 13 drugs in Pre-Registration. The Myopia pipeline products include three routes of administration with the top ROA being Ophthalmic and three key molecule types in the Myopia pipeline products market including Small Molecule, and Synthetic Peptide.
Myopia overview
Myopia, a form of nearsightedness, is a ophthalmological disorder that results in blurred vision when looking at distant objects. This occurs due to the improper refraction of light in the eye, causing the focal point to fall in front of the retina, rather than on it. Close-up objects can still be seen clearly. The underlying cause of myopia can be attributed to specific alterations in the SCO2 gene. Its inheritance pattern follows an autosomal dominant model, indicating that an individual carrying a single mutated copy of the gene is sufficient to manifest the condition. This genetic variation plays a pivotal role in the development of nearsightedness, impacting how the eye focuses light, ultimately affecting vision clarity.
For a complete picture of Myopia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
